H.I.G. Capital Veteran Rob Wolfson Secures $1.05 Billion for New Private Equity Platform

Aphias Capital, a San Francisco-based private equity firm founded by former H.I.G. Capital executive Rob Wolfson, announced the final close of its inaugural fund, securing more than $1.05 billion in commitments for investments in North American healthcare and essential services companies.

Aphias Capital Fund I exceeded its $900 million fundraising target by approximately 17%, with investor demand surpassing the fund’s undisclosed hard cap. The closing provides the emerging manager with substantial capital to pursue control investments in established lower-middle-market businesses.

Institutional Investors Back Aphias Capital Fund I

The fund attracted commitments from public pension plans, health systems, insurance companies, endowments, foundations, family offices, funds of funds and other institutional investors.

According to the official Aphias Capital fund closing announcement, the firm intends to acquire controlling stakes in businesses with $5 million to $30 million in earnings before interest, taxes, depreciation and amortization (EBITDA).

Healthcare & Essential Services PE

Aphias targets companies with recurring customer demand and opportunities to improve operations, expand technology adoption and accelerate organic growth.

PJT Park Hill acted as exclusive placement agent, while Kirkland & Ellis served as legal counsel.

The fundraising outcome is significant for a first-time institutional platform, particularly as private equity investors evaluate liquidity, manager selection and the pace of distributions from existing commitments.

SEC Filings Provide Additional Fundraising Detail

Regulatory disclosures provide greater precision on the size and structure of the inaugural fund.

October 2026 amendments to SEC Form D filings for Aphias Capital Fund I and its parallel vehicle report approximately $1.056 billion in aggregate securities sold, consistent with the announced closing amount.

The filings report 52 investors in the main vehicle and 38 in the parallel vehicle. Because the disclosed fundraising total is shared across both entities, the amounts should not be added together.

The records also identify Oct. 1, 2025, as the first-sale date, providing a documented starting point for the fundraising process.

These disclosures distinguish committed capital from deployed investment capital. They do not establish how much of the fund has already been invested in portfolio companies.

Lower-Middle-Market Strategy Centers on Operational Growth

Founder and Managing Partner Rob Wolfson previously held senior healthcare investment leadership roles at H.I.G. Capital. Aphias draws on that experience to pursue acquisitions of established services businesses rather than early-stage venture investments.

Its investment approach emphasizes operational improvements, technology adoption and strategic acquisitions to increase portfolio-company earnings.

The strategy enters a market attracting institutional capital. PE NEWSWIRE previously covered Siguler Guff’s $3 billion small-buyout fundraising, demonstrating investor interest in smaller businesses and specialist private equity strategies.

However, fund size introduces deployment considerations. Aphias must balance its available capital against the supply of suitable acquisition targets while maintaining underwriting discipline.

Smaller Buyouts Offer Opportunities and Risks

Aphias’ fundraising follows a shift in U.S. middle-market transaction activity.

PE NEWSWIRE reported a 70% increase in smaller U.S. buyout deal value during the second quarter of 2026, covering transactions valued between $25 million and $100 million.

The trend provides context for Aphias’ investment mandate, although its target companies may fall across a wider valuation range.

Smaller services businesses can offer opportunities for operational improvements and acquisitions, but competition, financing costs and limited exit options can affect investment returns.

For Aphias, the successful fundraise establishes institutional backing for its first investment vehicle. Performance will depend on acquisition pricing, portfolio-company growth and eventual realizations.

The fund’s closing represents a substantial fundraising milestone, but its investment results remain to be demonstrated.